Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models

Overview

Journal Cancer Genomics Proteomics

Specialties Biochemistry
Genetics
Oncology

Date 2023 Oct 27

PMID 37889067

Authors

Ioannis A Voutsadakis

Affiliations

Soon will be listed here.

Abstract

Background/aim: Breast cancers constitute heterogeneous tumor groups and their categorization in subtypes based on the expression of the estrogen (ER), progesterone (PR) and HER2 receptors has advanced therapeutics. Claudin-low breast cancer has been proposed as an additional subtype which is mostly ER, PR and HER2 negative, but its identification has not led to corresponding specific treatments yet.

Materials And Methods: Breast cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) were assessed for mRNA suppression of claudins and mRNA expression of ER and ERBB2 (the gene encoding HER2). The set of identified claudin-low cell lines were compared with representative ER-/ERBB2- cell lines for associated molecular alterations, gene dependencies through CRISPR and microRNA arrays and in vitro drug sensitivities using the Genomics of Drug Sensitivity in Cancer (GDSC) project.

Results: Claudin-low cell lines display up-regulation of mRNA expression of epithelial to mesenchymal transition (EMT) regulators. Methylation sensitive genes are down-regulated in claudin-low lines compared with other cell lines, without associated up-regulation of DNA methyltransferases. Dependency screen microarrays reveal dependencies of claudin-low cell lines on components of the cytoskeleton but no consistent dependencies in known oncogenes or tumor suppressors. Potential drug sensitivities revealed in the drug screens included sensitivities to WNT pathway modulators, tyrosine kinase cascade inhibitors and BET inhibitors. On the other hand, claudin-low cell lines showed resistance to deacetylase inhibitors.

Conclusion: Claudin-low cell line models duplicate features of claudin-low breast cancers and may serve as guides for identification of drugs worth exploring for further development.

References

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

Xiong Y, Motomura H, Tamori S, Ozaki A, Onaga C, Hara Y . High Expression of and Predicts a Poor Prognosis in Basal-like Breast Cancer. Anticancer Res. 2022; 42(11):5223-5232. DOI: 10.21873/anticanres.16029. View

Voutsadakis I . Comparison of Clinical Subtypes of Breast Cancer within the Claudin-Low Molecular Cluster Reveals Distinct Phenotypes. Cancers (Basel). 2023; 15(10). PMC: 10216296. DOI: 10.3390/cancers15102689. View

Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G . Breast cancer. Lancet. 2021; 397(10286):1750-1769. DOI: 10.1016/S0140-6736(20)32381-3. View

Zhao N, Powell R, Yuan X, Bae G, Roarty K, Stossi F . Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition. Nat Commun. 2021; 12(1):4262. PMC: 8275587. DOI: 10.1038/s41467-021-24545-3. View

Linares A, Assou S, Lapierre M, Thouennon E, Duraffourd C, Fromaget C . Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers. Mol Oncol. 2019; 13(7):1534-1547. PMC: 6599838. DOI: 10.1002/1878-0261.12505. View

Fougner C, Bergholtz H, Norum J, Sorlie T . Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020; 11(1):1787. PMC: 7156396. DOI: 10.1038/s41467-020-15574-5. View

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

Yun M, Wu J, Workman J, Li B . Readers of histone modifications. Cell Res. 2011; 21(4):564-78. PMC: 3131977. DOI: 10.1038/cr.2011.42. View

10.

Riaz M, van Jaarsveld M, Hollestelle A, Prager-van der Smissen W, Heine A, Boersma A . miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 2013; 15(2):R33. PMC: 3672661. DOI: 10.1186/bcr3415. View

11.

Voutsadakis I . The network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancer. Breast Cancer (Dove Med Press). 2015; 7:303-19. PMC: 4567227. DOI: 10.2147/BCTT.S71163. View

12.

Meyer T, Marshall J, Hart I . Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer. 1998; 77(4):530-6. PMC: 2149929. DOI: 10.1038/bjc.1998.86. View

13.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

14.

Wang W, Zheng Y, Sun S, Li W, Song M, Ji Q . A genome-wide CRISPR-based screen identifies as a driver of cellular senescence. Sci Transl Med. 2021; 13(575). DOI: 10.1126/scitranslmed.abd2655. View

15.

Asleh K, Riaz N, Nielsen T . Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022; 41(1):265. PMC: 9434975. DOI: 10.1186/s13046-022-02476-1. View

16.

Ohzeki J, Shono N, Otake K, Martins N, Kugou K, Kimura H . KAT7/HBO1/MYST2 Regulates CENP-A Chromatin Assembly by Antagonizing Suv39h1-Mediated Centromere Inactivation. Dev Cell. 2016; 37(5):413-27. PMC: 4906249. DOI: 10.1016/j.devcel.2016.05.006. View

17.

Rosso C, Fera N, Murugan N, Voutsadakis I . Vitamin D Levels in Newly Diagnosed Breast Cancer Patients according to Tumor Sub-Types. J Diet Suppl. 2022; 20(6):926-938. DOI: 10.1080/19390211.2022.2144582. View

18.

Xiao Y, Li W, Yang H, Pan L, Zhang L, Lu L . HBO1 is a versatile histone acyltransferase critical for promoter histone acylations. Nucleic Acids Res. 2021; 49(14):8037-8059. PMC: 8661427. DOI: 10.1093/nar/gkab607. View

19.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

20.

Nunez-Alvarez Y, Suelves M . HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes. FEBS J. 2021; 289(10):2771-2792. DOI: 10.1111/febs.15895. View